¼¼°èÀÇ ¸®Åö½Ã¸¿ ½ÃÀå
Rituximab
»óǰÄÚµå : 1798236
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 378 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,215,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,647,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¸®Åö½Ã¸¿ ½ÃÀåÀº 2030³â±îÁö 112¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 49¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ¸®Åö½Ã¸¿ ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 14.6%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 112¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ÇÇÇÏ Åõ¿©´Â CAGR 15.3%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 64¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Á¤¸Æ³» Åõ¿© ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 13.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 13¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 19.5%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¸®Åö½Ã¸¿ ½ÃÀåÀº 2024³â¿¡ 13¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 24¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 19.5%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 10.7%¿Í 13.1%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 11.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¸®Åö½Ã¸¿ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¸®Åö½Ã¸¿ÀÌ Ç¥Àû »ý¹°Á¦Á¦ÀÇ ÁøÈ­ÇÏ´Â »óȲ ¼Ó¿¡¼­µµ ¿©ÀüÈ÷ °­¼¼¸¦ º¸ÀÌ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

CD20 ¾ç¼º B¼¼Æ÷¸¦ Ç¥ÀûÀ¸·Î Çϴ Ű¸Þ¶ó ´ÜÀÏŬ·Ð Ç×üÀÎ ¸®Åö½Ã¸¿Àº Ç÷¾× ¾Ç¼º Á¾¾ç ¹× ÀÚ°¡¸é¿ªÁúȯ Ä¡·áÀÇ ÇÙ½ÉÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. Ãâ½Ã 20³âÀÌ Áö³­ ÇöÀç¿¡µµ ºñÈ£ÁöŲ¸²ÇÁÁ¾(NHL), ¸¸¼º ¸²ÇÁ±¸¼º ¹éÇ÷º´(CLL), ·ù¸¶Æ¼½º°üÀý¿°(RA), ´Ù¹ß¼º Ç÷°ü¿° À°¾ÆÁ¾Áõ µîÀÇ ÀûÀÀÁõ¿¡¼­ È®°íÇÑ Á¸Àç°¨À» º¸À̰í ÀÖ½À´Ï´Ù. »õ·Î¿î »ý¹°Á¦Á¦ ¹× ÀúºÐÀÚ ´ëü¾à¹°ÀÇ µîÀå¿¡µµ ºÒ±¸ÇÏ°í ¸®Åö½Ã¸¿Àº ÀÔÁõµÈ È¿°ú, Àß ¹®¼­È­µÈ ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏ, ±×¸®°í Àü ¼¼°è 1Â÷ Ä¡·á °¡À̵å¶óÀο¡ Æ÷ÇԵǸ鼭 ¿©ÀüÈ÷ ÇʼöÀûÀÎ Ä¡·áÁ¦·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

ÀÌ ¾àÀº Á¾¾çÇÐ ¹× ¸é¿ªÇÐ ºÐ¾ß¿¡¼­ ±¤¹üÀ§ÇÏ°Ô »ç¿ëµÇ¹Ç·Î ÀÌÁß ½ÃÀå ¿ìÀ§¸¦ °¡Áö°í ÀÖ½À´Ï´Ù. CD20À» Ç¥ÀûÀ¸·Î ÇÏ¿© Ç×ü ÀÇÁ¸¼º ¼¼Æ÷µ¶¼º(ADCC) ¹× º¸Ã¼ ÀÇÁ¸¼º ¼¼Æ÷µ¶¼º(CDC)À» ÅëÇØ B¼¼Æ÷ ¿ëÇØ¸¦ ¸Å°³ÇÏ´Â ±× ±âÀüÀº ƯÈ÷ B¼¼Æ÷ Á¶Àý Àå¾Ö¸¦ º¸À̴ ȯÀÚ¿¡¼­ ÀÓ»óÀûÀ¸·Î Áß¿äÇÑ Àǹ̸¦ Áö´Õ´Ï´Ù. ¶ÇÇÑ ÀÓ»ó½ÃÇèÀ» ÅëÇØ Àü½Å¼º È«¹Ý¼º ·çǪ½º(SLE), Ư¹ß¼º Ç÷¼ÒÆÇ°¨¼Ò¼º Àڹݺ´(ITP) µî ÀûÀÀÁõ ¿Ü Áúȯ¿¡ ´ëÇÑ »ç¿ëÀÌ Áö¼ÓÀûÀ¸·Î °­È­µÇ°í ÀÖÀ¸¸ç, ±× Ä¡·á ¿µ¿ªÀÌ ´õ¿í È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °æÀï¿¡µµ ºÒ±¸ÇÏ°í ¸®Åö½Ã¸¿ÀÇ Áö¼ÓÀûÀÎ ÀÓ»óÀû À¯¿ë¼ºÀº µ¶Æ¯ÇÑ ¾à·ÂÇаú °ü¸® °¡´ÉÇÑ µ¶¼ºÀ¸·Î ÀÎÇØ º´¿ë¿ä¹ý¿¡¼­ ½Å·ÚÇÒ ¼ö ÀÖ´Â Åø·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿À½Ã¹Ð·¯¿Í ÇÇÇÏÁÖ»çÁ¦´Â ¾î¶»°Ô ½ÃÀå ¿ªÇÐÀ» ÀçÆíÇϰí Àִ°¡?

¼¼°è ¸®Åö½Ã¸¿ ½ÃÀåÀº ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ µîÀåÀ¸·Î ±¸Á¶ÀûÀÎ º¯È­¸¦ °Þ°í ÀÖ½À´Ï´Ù. À¯·´, Àεµ, ÀϺ», ¹Ì±¹ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ¸·Î Truxima, Ruxience, Reditux¿Í °°Àº ºñ¿ë È¿À²ÀûÀÎ ´ëüǰÀÇ ÁøÀÔÀÌ ÃËÁøµÇ¾î °ø°ø ÀÇ·á ½Ã½ºÅÛ ¹× ¹Î°£ Á¾¾ç Ŭ¸®´Ð¿¡¼­ ºü¸£°Ô È®»êµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰÀº ÁßÀú¼Òµæ ±¹°¡ÀÇ »ý¹°Á¦Á¦ Á¢±Ù¼º ¹ÎÁÖÈ­¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ¿À¸®Áö³Î Á¦¾à»ç¿¡°Ô °¡°Ý Ã¥Á¤ ¹× ÆÇ¸Å Àü·«ÀÇ Àç°ËÅ並 ¿ä±¸Çϰí ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ Áß¿äÇÑ Ãß¼¼´Â Á¤¸Æ Åõ¿©¿¡¼­ ÇÇÇÏ Åõ¿©·ÎÀÇ ÀüȯÀ¸·Î, ȯÀÚÀÇ ÆíÀǼºÀ» Çâ»ó½Ã۰í, º´¿ø ÀÔ¿ø ½Ã°£À» ´ÜÃàÇϰí, Åõ¿© ºñ¿ëÀ» ³·Ãß´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ÇÇÇÏ Åõ¿© ¸®Åö½Ã¸¿Àº Ç×ü¸¦ È÷¾Ë·ç·Î´Ï´ÙÁ¦¿Í °áÇÕ½ÃÄÑ ´õ »¡¸® Èí¼öµÇµµ·Ï ÇÏ´Â °ÍÀ¸·Î, ÀϺΠÁö¿ª¿¡¼­ ÀÓ»ó ½ÂÀÎÀ» ¹Þ¾ÒÀ¸¸ç ȯÀÚµéÀÌ ¼±È£Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â ƯÈ÷ ¿Ü·¡ ¼ö¾× ¼¾ÅÍÀÇ ºÎ´ãÀÌ Å« °í¼Òµæ ±¹°¡¿¡¼­ ÀçÅà Åõ¿© ¸ðµ¨À» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, È­Çпä¹ý Áֱ⸦ °£¼ÒÈ­ÇÏ°í º¹ÀâÇÑ Ä¡·á ¿ä¹ýÀÇ ¼øÀÀµµ¸¦ ³ôÀ̱â À§ÇØ ¸®Åö½Ã¸¿°ú ´Ù¸¥ ¾à¹°À» °áÇÕÇÑ Å°Æ® Á¦Á¦°¡ °ËÅäµÇ°í ÀÖ½À´Ï´Ù.

¼ö¿ä ´Ùº¯È­¸¦ ÃËÁøÇÏ´Â ÀûÀÀÁõ°ú Áö¿ª ½ÃÀåÀº?

B¼¼Æ÷ ¸²ÇÁÁ¾ÀÌ ¸®Åö½Ã¸¿ÀÇ ÁÖ¿ä ¿µ¿ªÀÎ °ÍÀº º¯ÇÔ¾øÁö¸¸, ÀÚ°¡¸é¿ªÁúȯ¿¡¼­ÀÇ »ç¿ëµµ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ·ù¸¶Æ¼½º °üÀý¿°, ƯÈ÷ Ç÷û ¾ç¼º ȯÀÚ¿¡¼­ TNF ¾ïÁ¦Á¦¿¡ ÀÌ¾î µÎ ¹øÂ° ¼±Åþ๰·Î¼­ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ç÷°ü¿° ÁõÈıºÀ̳ª ´Ù¹ß¼º °æÈ­Áõ, ƯÈ÷ ´Ù¸¥ Áúȯ Á¶Àý ¾à¹°¿¡ ºÒ³»¼ºÀ̳ª ºñ¹ÝÀÀÀÌ Àִ ȯÀڵ鿡°Ôµµ ¸¹ÀÌ °í·ÁµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â ¿©·¯ Àü¹®ÀǵéÀÌ ¸®Åö½Ã¸¿ÀÇ »ç¿ëÀ» Á¾¾ç³»°ú»Ó¸¸ ¾Æ´Ï¶ó ·ù¸¶Æ¼½º³»°ú, ½Å°æ°ú µîÀ¸·Î È®´ëÇÏ´Â °è±â°¡ µÇ°í ÀÖ½À´Ï´Ù.

Áö¿ªº°·Î´Â À¯·´ÀÌ ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰ äÅÃÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, ±¹°¡ ÀÔÂû ¹× °øÀû º¸ÇèÁ¦µµ¸¦ ÅëÇØ Ç¥Áؾ๰ÀÎ ¸®Åö½Ã¸¿ÀÇ ´ëü°¡ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. Àεµ¿Í ºê¶óÁúÀº ±¹³» Á¦Á¶ ¹× ±¹°¡ Á¶´Þ ÇÁ·Î±×·¥À» ÅëÇØ »ó´çÇÑ ¹°·® Áõ°¡¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÇÑÆí, ºÏ¹Ì, ƯÈ÷ ¹Ì±¹¿¡¼­´Â ¹ÙÀÌ¿À½Ã¹Ð·¯°¡ º´¿ø ó¹æ¿¡ ºü¸£°Ô ħÅõÇϰí ÀÖ´Â ¹Ý¸é, ¿©ÀüÈ÷ ¿À¸®Áö³Î ÀǾàǰÀÎ ¸®Åö»êÀÌ ÁÖ·ù¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ¾ÆÇÁ¸®Ä«¿Í µ¿³²¾Æ½Ã¾Æ¿¡¼­´Â ¼ö¿ä°¡ ¼¼°è ¾×¼¼½º ÇÁ·Î±×·¥°ú WHOÀÇ »çÀü ½ÂÀΰú ¿¬°èµÇ¾î ÀÚ¿øÀÌ ºÎÁ·ÇÑ È¯°æ¿¡¼­ ¸²ÇÁÁ¾¿¡ ´ëÇÑ ¸®Åö½Ã¸¿ÀÇ °¡¿ë¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌó·³ °¡°Ý, ±ÔÁ¦, ÀÓ»ó °üÇàÀÌ ¼­·Î ´Ù¸¥ ½ÃÀåµé »çÀÌ¿¡¼­ ´ÙÃþÀûÀ¸·Î ¼ºÀåÇϰí ÀÖ´Â °ÍÀº ÀÌ ¾à¹°ÀÌ Àü ¼¼°è¿¡¼­ Áß¿äÇÏ´Ù´Â °ÍÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå È®´ë¿Í Ä¡·á ÃÖÀûÈ­¸¦ Áö¿øÇÏ´Â Àü·«Àû ¿äÀÎÀº ¹«¾ùÀΰ¡?

¸®Åö½Ã¸¿ ½ÃÀåÀÇ ¼ºÀåÀº ¸²ÇÁ Áõ½Ä¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, ÀÚ°¡¸é¿ªÁúȯÀÇ Áø´Ü °³¼±, ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ º¸±Þ È®´ë, Á¦Çü Çõ½Å µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¸®Åö½Ã¸¿Àº ¾Ç¼º Á¾¾ç°ú ¸é¿ªÁúȯÀ» ´ë»óÀ¸·Î ÇÑ Ä¡·á °¡À̵å¶óÀο¡ ²ÙÁØÈ÷ Æ÷ÇԵǸ鼭 ÀÓ»óÀǵéÀÇ ½Å·Ú°¡ Èçµé¸®Áö ¾Ê°í ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿©·¯ ¿°Áõ °æ·Î¿¡¼­ Ãʱâ B¼¼Æ÷ÀÇ °ü¿©¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ »õ·Î¿î ÀÚ°¡¸é¿ªÁúȯ¿¡ ´ëÇÑ ÀçÁ¶¸íÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù.

ÀǾàǰ Àü·«Àº º´¿ë½ÃÇè, ½Çµ¥ÀÌÅÍ ½ÃÇè, ¹ÙÀÌ¿À½Ã¹Ð·¯ ÃÖÀûÈ­¸¦ ÅëÇÑ ¼ö¸íÁֱ⠿¬Àå¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ÀϺΠÁ¦Á¶¾÷üµéÀº Àå±â »ç¿ë½Ã ¾ÈÀü¼º ¸ð´ÏÅ͸µÀ» °­È­Çϱâ À§ÇØ SC Á¦Á¦ °³¼±, ÇÕÁ¦, AI¸¦ Ȱ¿ëÇÑ ¾à¹°°¨½Ã¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, Á¤ºÎ ¹× NGO´Â ¾Ï ÀÇ·á Á¢±Ù¼º ÇÁ·Î±×·¥¿¡ µû¶ó ¸®Åö½Ã¸¿ Á¶´ÞÀ» À§ÇÑ ÀÚ±ÝÀ» Áö¿øÇϰí ÀÖÀ¸¸ç, ƯÈ÷ ¼Ò¿ÜµÈ ½ÃÀå¿¡¼­ ¸®Åö½Ã¸¿ Á¶´ÞÀ» À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿¬±¸°³¹ß, Á¤Ã¥, Á¢±Ù¼º¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ³ë·ÂÀº ¸®Åö½Ã¸¿ÀÌ ÁÖ·Â Ä¡·áÁ¦·Î¼­ÀÇ ÁöÀ§¸¦ À¯ÁöÇÏ´Â µ¿½Ã¿¡ °æÀï°ú °æÁ¦Àû ¾Ð¹Ú¿¡ Á÷¸éÇÑ »óȲ¿¡¼­ ¸®Åö½Ã¸¿ÀÇ ÁøÈ­¸¦ Áö¿øÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Åõ¿© °æ·Î(ÇÇÇÏ Åõ¿©, Á¤¸Æ³» Åõ¿©, ºñ°æ±¸Åõ¿©), À¯Åë ä³Î(º´¿ø ¾à±¹, ¿Â¶óÀÎ ¾à±¹, ±âŸ À¯Åë ä³Î), ¿ëµµ(ºñÈ£ÁöŲ¸²ÇÁÁ¾, ¸¸¼º ¸²ÇÁ¼º ¹éÇ÷º´, ·ù¸¶Æ¼½º °üÀý¿°, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Rituximab Market to Reach US$11.2 Billion by 2030

The global market for Rituximab estimated at US$4.9 Billion in the year 2024, is expected to reach US$11.2 Billion by 2030, growing at a CAGR of 14.6% over the analysis period 2024-2030. Subcutaneous Administration, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$6.4 Billion by the end of the analysis period. Growth in the Intravenous Administration segment is estimated at 13.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 19.5% CAGR

The Rituximab market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 19.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.7% and 13.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.6% CAGR.

Global Rituximab Market - Key Trends & Drivers Summarized

Why Is Rituximab Still Holding Strong in the Evolving Landscape of Targeted Biologics?

Rituximab, a chimeric monoclonal antibody targeting CD20-positive B cells, continues to be a cornerstone in the treatment of hematological malignancies and autoimmune disorders. Even two decades after its introduction, it maintains a solid presence across indications such as non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and granulomatosis with polyangiitis. Despite the emergence of newer biologics and small-molecule alternatives, rituximab remains indispensable due to its proven efficacy, well-documented safety profile, and inclusion in first-line therapy guidelines globally.

The drug's broad usage in both oncology and immunology offers it a dual-market advantage. Its mechanism-targeting CD20 to mediate B-cell lysis through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC)-has remained clinically relevant, especially in patients exhibiting B-cell dysregulation. Moreover, clinical trials continue to reinforce its use in off-label conditions like systemic lupus erythematosus (SLE) and idiopathic thrombocytopenic purpura (ITP), further expanding its therapeutic footprint. Despite competition, rituximab’s enduring clinical utility is attributed to its unique pharmacodynamics and manageable toxicity, making it a reliable tool in combination regimens.

How Are Biosimilars and Subcutaneous Formulations Reshaping Market Dynamics?

The global rituximab market is undergoing a structural shift due to the advent of biosimilars. Regulatory approvals across Europe, India, Japan, and the U.S. have facilitated the entry of cost-effective alternatives such as Truxima, Ruxience, and Reditux, which have quickly gained traction in both public health systems and private oncology clinics. These biosimilars are helping to democratize access to biologic therapies in low- and middle-income countries and are compelling originator companies to revisit pricing and distribution strategies.

Another pivotal trend is the transition from intravenous (IV) to subcutaneous (SC) formulations, aimed at improving patient convenience, reducing hospital chair time, and lowering administration costs. Subcutaneous rituximab, combining the antibody with hyaluronidase for faster absorption, has gained clinical approval and patient preference in several regions. This shift is fostering home-based administration models, particularly in high-income countries with overburdened outpatient infusion centers. Meanwhile, combination products that include rituximab with other agents in pre-packaged kits are being explored to streamline chemotherapy cycles and enhance compliance in complex treatment regimens.

Which Indications and Regional Markets Are Driving Demand Diversification?

While B-cell lymphomas remain the primary domain for rituximab, its usage in autoimmune diseases is gaining pace. In rheumatoid arthritis, it serves as a second-line option after TNF inhibitors, especially in seropositive patients. It is also being increasingly considered for vasculitis syndromes and multiple sclerosis, particularly in patients with intolerance or non-responsiveness to other disease-modifying agents. This shift is encouraging multi-specialty adoption, extending rituximab use beyond oncology to rheumatology and neurology practices.

Regionally, Europe has led in biosimilar adoption, with national tenders and public insurance schemes accelerating substitution from reference rituximab. India and Brazil have seen significant volume growth driven by domestic manufacturing and state procurement programs. Meanwhile, North America-especially the U.S.-still sees dominant use of branded Rituxan, although biosimilars are rapidly encroaching into hospital formularies. In Africa and Southeast Asia, demand is tied to global access programs and WHO prequalification, which are expanding rituximab availability for lymphomas under resource-limited settings. This layered growth across markets with varied pricing, regulatory, and clinical practices underscores the drug's global relevance.

What Strategic Factors Are Sustaining Market Expansion and Therapy Optimization?

The growth in the rituximab market is driven by several factors, including increasing prevalence of lymphoproliferative disorders, improved diagnosis of autoimmune diseases, expanding biosimilar penetration, and formulation innovation. The steady inclusion of rituximab in evolving treatment guidelines for both malignancies and immune-mediated conditions ensures sustained clinician trust and widespread usage. Moreover, growing awareness of early B-cell involvement in multiple inflammatory pathways is encouraging its repositioning in newer autoimmune indications.

Pharmaceutical strategies are focusing on lifecycle extension through combination trials, real-world data studies, and biosimilar optimization. Several manufacturers are investing in SC formulation improvements, fixed-dose combinations, and AI-enabled pharmacovigilance to enhance safety monitoring in long-term use. Meanwhile, governments and NGOs are funding rituximab procurement under cancer care access programs, especially in underserved markets. These combined efforts-across R&D, policy, and access-are sustaining rituximab’s status as a mainstay therapy while supporting its evolution in the face of competitive and economic pressures.

SCOPE OF STUDY:

The report analyzes the Rituximab market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Administration Route (Subcutaneous Administration, Intravenous Administration, Parenteral Administration); Distribution Channel (Hospitals Pharmacy, Online Pharmacy, Other Distribution Channels); Application (Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application, Rheumatoid Arthritis Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â